- CCXI To Face FDA In April, CRDF Soars On Colorectal Cancer Trial Data, VCNX In Deal With MRK - Nasdaq
- Coronavirus in cats? - Pursuit
- Seeking clarity on retinal findings in patients with COVID-19 - The Lancet
- Regulatory actions for Sept. 17, 2020 | 2020-09-17 - BioWorld Online
- FDA accepts avacopan NDA for ANCA-associated vasculitis - Healio
- Natalie A. Marks, MD is recognized by Continental Who's Who - Yahoo Finance
- Capital Health Medical Group adds 3 fellowship-trained rheumatologists to specialty practice - Community News
- A Veteran's Voice - Andy Selga - KERO 23ABC News
- FDA accepts ChemoCentryx's avacopan application for blood vessel inflammation - Seeking Alpha
- ChemoCentryx (CCXI) Reports FDA Acceptance of the Avacopan NDA for Treatment of ANCA-Associated Vasculitis - StreetInsider.com
- ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis - GlobeNewswire
- Vasculitis Treatment Market 2020 Size, Future Demand, Global Research, Top Leading player, Emerging Trends, Region by Forecast to 2027 - The Daily Chronicle
- The trend of cutaneous lesions during COVID‐19 pandemic: lessons from a meta‐analysis and systematic review - wiley.com
- Nine-hour burpee challenge sees sister raise £3,000 to help with brother's rare disease - Portsmouth News
- Harold Ramis: 1944-2014 - POP TIMES UK
Connect with us on social media!
Participate in Research
The Vasculitis Foundation's updated website design was generously funded with a grant by Genentech.
